ProKidney (NASDAQ:PROK) Posts Earnings Results, Misses Expectations By $0.04 EPS

ProKidney (NASDAQ:PROK) released its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04), FiscalAI reports. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.12 million.

ProKidney Stock Up 1.8%

PROK traded up $0.02 on Thursday, hitting $1.15. The company’s stock had a trading volume of 1,086,887 shares, compared to its average volume of 1,136,153. The company’s 50 day simple moving average is $1.56 and its 200-day simple moving average is $1.78. The firm has a market cap of $347.67 million, a P/E ratio of -2.09 and a beta of 1.90. ProKidney has a 12 month low of $0.87 and a 12 month high of $2.65.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ProKidney in a research report on Tuesday, October 6th. Citigroup dropped their target price on shares of ProKidney to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Insiders Place Their Bets

In other ProKidney news, Director Brian Pereira sold 229,338 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $1.37, for a total transaction of $314,193.06. Following the sale, the director owned 445,897 shares of the company’s stock, valued at $610,878.89. The trade was a 33.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 757,164 shares of company stock valued at $1,067,315. 39.83% of the stock is currently owned by insiders.

ProKidney Company Profile

ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.